Anti-amyloid-β Monoclonal Antibodies as Promising Disease-Modifying Therapies in Alzheimer's Disease: A Focus on Aducanumab, Lecanemab, Crenezumab, Gantenerumab and Solanezumab

被引：1
|
作者：
Melo, V. S. D. [1 ]
Rodrigues, C. A. [1 ]
Silva, I. A. [2 ]
机构：
[1] Ctr Hosp Medio Tejo, Psychiat, Tomar, Portugal
[2] Unidade Local Saude Norte Alentejano, Psychiat, Portalegre, Portugal
来源：
EUROPEAN PSYCHIATRY | 2023年 / 66卷
关键词：
D O I：
10.1192/j.eurpsy.2023.663
中图分类号：
R749 [精神病学];
学科分类号：
100205 ;
摘要：
EPP0346
引用
收藏
页码：S297 / S297
页数：1
相关论文
共 50 条
  • [1] Anti-amyloid-β Monoclonal Antibodies as Promising Disease-Modifying Therapies in Alzheimer's Disease: A Focus on Aducanumab, Lecanemab, Crenezumab, Gantenerumab and Solanezumab
    Melo, V. S. D.
    Rodrigues, C. A.
    Silva, I. A.
    EUROPEAN PSYCHIATRY, 2023, 66 : S297 - S297
  • [2] Impact of Anti-amyloid-β Monoclonal Antibodies on the Pathology and Clinical Profile of Alzheimer's Disease: A Focus on Aducanumab and Lecanemab
    Shi, Mingchao
    Chu, Fengna
    Zhu, Feiqi
    Zhu, Jie
    FRONTIERS IN AGING NEUROSCIENCE, 2022, 14
  • [3] Gantenerumab: an anti-amyloid monoclonal antibody with potential disease-modifying effects in early Alzheimer's disease
    Bateman, Randall J.
    Cummings, Jeffrey
    Schobel, Scott
    Salloway, Stephen
    Vellas, Bruno
    Boada, Merce
    Black, Sandra E.
    Blennow, Kaj
    Fontoura, Paulo
    Klein, Gregory
    Assuncao, Sheila Seleri
    Smith, Janice
    Doody, Rachelle S.
    ALZHEIMERS RESEARCH & THERAPY, 2022, 14 (01)
  • [4] Gantenerumab: an anti-amyloid monoclonal antibody with potential disease-modifying effects in early Alzheimer’s disease
    Randall J. Bateman
    Jeffrey Cummings
    Scott Schobel
    Stephen Salloway
    Bruno Vellas
    Mercè Boada
    Sandra E. Black
    Kaj Blennow
    Paulo Fontoura
    Gregory Klein
    Sheila Seleri Assunção
    Janice Smith
    Rachelle S. Doody
    Alzheimer's Research & Therapy, 14
  • [5] Anti-Amyloid-β Monoclonal Antibodies for Alzheimer's Disease: Pitfalls and Promise
    van Dyck, Christopher H.
    BIOLOGICAL PSYCHIATRY, 2018, 83 (04) : 311 - 319
  • [6] Alzheimer's disease: Progress in the development of anti-amyloid disease-modifying therapies
    Christensen, Daniel D.
    CNS SPECTRUMS, 2007, 12 (02) : 113 - +
  • [7] New horizons for Alzheimer's disease: Potential disease-modifying anti-amyloid therapies
    Orgogozo, J-M.
    Golde, T. E.
    Wilcock, G.
    EUROPEAN JOURNAL OF NEUROLOGY, 2007, 14 : 327 - 327
  • [8] Disease-modifying therapies in Alzheimer's disease
    Salloway, Stephen
    Mintzer, Jacobo
    Weiner, Myron F.
    Cummings, Jeffrey L.
    ALZHEIMERS & DEMENTIA, 2008, 4 (02) : 65 - 79
  • [9] Anti-amyloid- βAntibodies and Anti-tau Therapies for Alzheimer's Disease: Recent Advances and Perspectives
    Suzuki, Naoyuki
    Hatta, Takuya
    Ito, Mana
    Kusakabe, Ken-ichi
    CHEMICAL & PHARMACEUTICAL BULLETIN, 2024, 72 (07) : 602 - 609
  • [10] Promising disease-modifying therapies for Parkinson's disease
    Dawson, Valina L.
    Dawson, Ted M.
    SCIENCE TRANSLATIONAL MEDICINE, 2019, 11 (520)
12345